SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution

PLoS Computational Biology

Volumn 10, Issue 8, 2014, Pages

  Miller, Christopher A ^a   White, Brian S ^a,b   Dees, Nathan D ^a   Griffith, Malachi ^a   Welch, John S ^b,c   Griffith, Obi L ^a,b   Vij, Ravi ^b,c   Tomasson, Michael H ^b,c   Graubert, Timothy A ^b,c,d   Walter, Matthew J ^a,b,c   Ellis, Matthew J ^b,c   Schierding, William ^e   DiPersio, John F ^b,c   Ley, Timothy J ^a,b,c   Mardis, Elaine R ^a,b,c   Wilson, Richard K ^a,b,c   Ding, Li ^a,b,c  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MO   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; PATIENT TREATMENT;

FINE RESOLUTION; MASSIVELY PARALLEL SEQUENCING; MULTIPLE SAMPLES; NEOPLASTIC CELLS; SOMATIC MUTATION; SPATIAL AND TEMPORAL PATTERNS; SUBCLONES; TREATMENT RESPONSE; TUMOR HETEROGENEITY; TUMOR TREATMENT;

TUMORS;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BAYES THEOREM; BREAST CANCER; CANCER MORPHOLOGY; CANCER RECURRENCE; CANCER RESISTANCE; CLONAL EVOLUTION; DATA ANALYSIS SOFTWARE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC VARIABILITY; INTERMETHOD COMPARISON; SOMATIC MUTATION; TUMOR BIOPSY; UNCERTAINTY; BIOLOGY; BREAST TUMOR; CLASSIFICATION; FEMALE; GENETICS; HUMAN; MUTATION; NEOPLASM; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PROCEDURES; STATISTICAL MODEL;

BREAST NEOPLASMS; CLONAL EVOLUTION; COMPUTATIONAL BIOLOGY; FEMALE; GENE FREQUENCY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MODELS, STATISTICAL; MUTATION; NEOPLASMS; NEOPLASTIC PROCESSES;

EID: 84952310964     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003665     Document Type: Article

References (59)

1. Nowell PC, (1976) The clonal evolution of tumor cell populations. Science 194: 23–8.
2. Greaves M, Maley CC, (2012) Clonal evolution in cancer. Nature 481: 306–13.
3. Gerlinger M, Swanton C, (2010) How darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 103: 1139–43.
4. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, et al. (2012) The origin and evolution of mutations in acute myeloid leukemia. Cell 150: 264–78.
5. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, et al. (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481: 506–10.
6. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, et al. (2012) The life history of 21 breast cancers. Cell 149: 994–1007.
7. Campbell PJ, Pleasance ED, Stephens PJ, Dicks E, Rance R, et al. (2008) Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A 105: 13081–6.
8. Ding L, Ellis MJ, Li S, Larson DE, Chen K, et al. (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464: 999–1005.
9. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114–7.
10. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, et al. (2013) Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152: 714–26.
11. Shah SP, Roth A, Goya R, Oloumi A, Ha G, et al. (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486: 395–9.
12. Egan JB, Shi CX, TembeW, Christoforides A, Kurdoglu A, et al. (2012) Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 120: 1060–6.
13. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883–92.
14. Walter MJ, Shen D, Shao J, Ding L, White BS, et al. (2013) Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 27: 1275–1282.
15. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, et al. (2011) Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469: 356–61.
16. Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, et al. (2010) Inferring tumor progression from genomic heterogeneity. Genome Res 20: 68–80.
17. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, et al. (2012) Clonal competition with alternating dominance in multiple myeloma. Blood 120: 1067–76.
18. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, et al. (2011) Tumour evolution inferred by single-cell sequencing. Nature 472: 90–4.
19. Xu X, Hou Y, Yin X, Bao L, Tang A, et al. (2012) Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148: 886–95.
20. Hughes AE, Magrini V, Demeter R, Miller CA, Fulton R, et al. (2014) Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet 10: e1004462.
21. Hou Y, Song L, Zhu P, Zhang B, Tao Y, et al. (2012) Single-cell exome sequencing and monoclonal evolution of a jak2-negative myeloproliferative neoplasm. Cell 148: 873–85.
22. Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, et al. (2014) Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 5: 2997.
23. Fisher R, Pusztai L, Swanton C, (2013) Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 108: 479–85.
24. Ma QC, Ennis CA, Aparicio S, (2012) Opening pandora's box–the new biology of driver mutations and clonal evolution in cancer as revealed by next generation sequencing. Curr Opin Genet Dev 22: 3–9.
25. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C, (2012) Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 4: 127ps10.
26. Merlo LM, Shah NA, Li X, Blount PL, Vaughan TL, et al. (2010) A comprehensive survey of clonal diversity measures in barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) 3: 1388–97.
27. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, et al. (2010) Preexistence and clonal selection of met amplification in egfr mutant nsclc. Cancer Cell 17: 77–88.
28. Su KY, Chen HY, Li KC, Kuo ML, Yang JC, et al. (2012) Pretreatment epidermal growth factor receptor (egfr) t790m mutation predicts shorter egfr tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 30: 433–40.
29. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, et al. (2002) Several types of mutations of the abl gene can be found in chronic myeloid leukemia patients resistant to sti571, and they can pre-exist to the onset of treatment. Blood 100: 1014–8.
30. Roth A, Khattra J, Yap D, Wan A, Laks E, et al. (2014) Pyclone: statistical inference of clonal population structure in cancer. Nat Meth 11: 396–398.
31. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, et al. (2012) Absolute quantification of somatic dna alterations in human cancer. Nat Biotechnol 30: 413–21.
32. Oesper L, Mahmoody A, Raphael BJ, (2013) Theta: inferring intra-tumor heterogeneity from high-throughput dna sequencing data. Genome Biology 14: R80.
33. Magrangeas F, Avet-Loiseau H, Gouraud W, Lode L, Decaux O, et al. (2013) Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 27: 473–81.
34. Van Loo P, Nordgard SH, Lingjaerde OC, Russnes HG, Rye IH, et al. (2010) Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A 107: 16910–5.
35. Klambauer G, Schwarzbauer K, Mayr A, Clevert D, Mitterecker A, et al. (2012) cn.mops: mixture of poissons for discovering copy number variations in next generation sequencing data with a low false discovery rate. Nucleic Acids Research 40: e69.
36. de Ligt J, Boone PM, Pfundt R, Vissers LELM, Richmond T, et al. (2013) Detection of clinically relevant copy number variants with whole-exome sequencing. Human Mutation 34: 1439–1448.
37. Guo Y, Sheng Q, Samuels DC, Lehmann B, Bauer JA, et al. (2013) Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. BioMed Research International 2013: 915636.
38. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, et al. (2012) Varscan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22: 568–76.
39. Ha G, Roth A, Lai D, Bashashati A, Ding J, et al. (2012) Integrative analysis of genome-wide loss of heterozygosity and mono-allelic expression at nucleotide resolution reveals disrupted pathways in triple negative breast cancer. Genome Research 22: 1995–2007.
40. Bishop CM (2006) Pattern recognition and machine learning. Information science and statistics. New York: Springer. 738 p. pp.
41. Gelman A, Carlin JB, Stern HS, Rubin DB (2004) Bayesian data analysis. Boca Raton, Florida: Chapman & Hall/CRC.
42. Beal MJ (2003) Variational algorithms for approximate bayesian inference. Ph.D. thesis, University College London.
43. Ma Z, Leijon A, (2011) Bayesian estimation of beta mixture models with variational inference. IEEE Trans Pattern Anal Mach Intell 33: 2160–73.
44. Fan W, Bouguila N, Ziou D, (2012) Variational learning for finite dirichlet mixture models and applications. IEEE Trans Neural Netw Learn Syst 23: 762–774.
45. Korenblum D, Shalloway D, (2003) Macrostate data clustering. Phys Rev E 67: 056704.
46. White BS, Shalloway D, (2009) Efficient uncertainty minimization for fuzzy spectral clustering. Phys Rev E Stat Nonlin Soft Matter Phys 80: 056705.
47. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, et al. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361: 1058–66.
48. Jiao W, Vembu S, Deshwar AG, Stein L, Morris Q (2013). Inferring clonal evolution of tumors from single nucleotide somatic mutations. Available: http://arxiv.org/abs/1210.3384.
49. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, et al. (2012) Comphrehensive molecular portraits of human breast tumours. Nature 490: 61–70.
50. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497: 67–73.
51. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, et al. (2010) Idh1 and idh2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with npm1 mutation without flt3 internal tandem duplication. J Clin Oncol 28: 3636–43.
52. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, et al. (2010) The common feature of leukemia-associated idh1 and idh2 mutations is a neomorphic enzyme activity converting alphaketoglutarate to 2-hydroxyglutarate. Cancer Cell 17: 225–34.
53. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, et al. (2013) Targeted inhibition of mutant idh2 in leukemia cells induces cellular differentiation. Science 340: 622–6.
54. Svensén M, Bishop CM, (2005) Robust bayesian mixture modelling. Trends in Neurocomputing 64: 235–252.
55. Lee J, Hoi CS, Lilja KC, White BS, Lee SE, et al. (2013) Runx1 and p21 synergistically limit the extent of hair follicle stem cell quiescence in vivo. Proc Natl Acad Sci U S A 110: 4634–9.
56. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, et al. (2013) Emerging landscape of oncogenic signatures across human cancers. Nat Genet 45: 1127–1133.
57. Griffith M, Griffith O, Coffman A, Weible J, McMichael J, et al. (2013) Dgidb: mining the druggable genome. Nat Methods 10: 1209–1210.
58. Attias H (1999) Inferring parameters and structure of latent variable models by variational bayes.In: Uncertainty in Artificial Intelligence. pp. 21–30.
59. Attias H (2000) A variational bayesian framework for graphical models. In: Neural Information Processing Systems.